HomeNewsIndiaReports of rising COVID-19 cases in China a concern but India need not panic given excellent vaccination coverage: SII CEO Adar Poonawalla

Reports of rising COVID-19 cases in China a concern but India need not panic given excellent vaccination coverage: SII CEO Adar Poonawalla

Adar Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of positive samples to keep track of newer variants, if any, amid a spurt in cases in the US and China.

December 21, 2022 / 14:03 IST
Story continues below Advertisement
Adar Poonawalla, 41, is the CEO of vaccine-manufacturer Serum Institute of India
Adar Poonawalla, 41, is the CEO of vaccine-manufacturer Serum Institute of India

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent.

Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of positive samples to keep track of newer variants, if any, amid a spurt in cases in the US and China.

Story continues below Advertisement

"The news of rising COVID cases coming out of China is concerning, we need not panic given our excellent vaccination coverage and track record. We must continue to trust and follow the guidelines set by the Government of India and @MoHFW_INDIA," Poonawalla tweeted.

During the COVID-19 pandemic, the Pune-based SII had collaborated with Oxford University and pharmaceutical company Astra Zeneca for making the Covishield vaccine.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show